NYSEAMERICAN : CANF
Can-Fite BioPharma Ltd. — Key statistics
Healthcare · Biotechnology · Israel
Last price 1.69 USD (Oct 30, 2026, 8:32 AM EDT) · Market cap 5.22M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 5.08M |
| Enterprise Value | -1.55M |
Dates
| Measure | Value |
|---|
| Earnings Date | Sep 8, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 4.29M |
| Shares Change (YoY) | +196.15% |
| Shares Change (QoQ) | +72.20% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 2.82% |
| Float | 6.06M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12.54 |
| Forward PS | 25.14 |
| PB Ratio | 1.05 |
| P/TBV Ratio | 1.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.60 |
| Quick Ratio | 3.17 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -211.37% |
| Return on Assets (ROA) | -77.12% |
| Return on Invested Capital (ROIC) | -132.55% |
| Return on Capital Employed (ROCE) | -166.93% |
| Weighted Average Cost of Capital (WACC) | 4.10% |
| Revenue Per Employee | $81,000 |
| Profits Per Employee | -$1.91M |
| Employee Count | 5 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.02 |
| 52-Week Price Change | -81.55% |
| 50-Day Moving Average | 2.26 |
| 200-Day Moving Average | 3.21 |
| Relative Strength Index (RSI) | 23.54 |
| Average Volume (20 Days) | 69,810 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 33,776 |
| Short Previous Month | 59,379 |
| Short % of Shares Out | 1.12% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.84 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 405,000 |
| Gross Profit | 405,000 |
| Operating Income | -9.73M |
| Pretax Income | -9.55M |
| Net Income | -9.55M |
| EBITDA | -9.73M |
| EBIT | -9.73M |
| Loss Per Share | -$6.17 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 7.04M |
| Total Debt | 49,000 |
| Net Cash | 6.99M |
| Net Cash Per Share | $1.63 |
| Equity (Book Value) | 4.86M |
| Book Value Per Share | 1.13 |
| Working Capital | 5.78M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -9.51M |
| Capital Expenditures | -2,000 |
| Depreciation & Amortization | 2,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -9.51M |
| FCF Per Share | -$2.22 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -2,402.96% |
| Pretax Margin | -2,358.77% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -196.15% |
| Shareholder Yield | -196.15% |
| Earnings Yield | -380.94% |
| FCF Yield | -187.31% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $7.50 |
| Price Target Difference | 362.96% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 235.26% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jan 5, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -32.41 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |